ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
87.505
-0.20%
Bitcoin
62,530.91
-0.91%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Inozyme Pharma Inc (INZY)

  7. Inozyme Pharma Inc (INZY) News

Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

NASDAQ
4.44
0.11
(2.54%)
Closed April 29 4:00PM
Delayed by 15 minutes
4.44
0.00
(0.00%)
After Hours: 7:58PM
Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

INZY News

Official News Only

Form EFFECT - Notice of Effectiveness
Edgar (US Regulatory)
November 16 2023
INZY (2.54%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
November 07 2023
INZY (2.54%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 07 2023
INZY (2.54%)

Form 8-K - Current report
Edgar (US Regulatory)
November 07 2023
INZY (2.54%)

INZY Discussion

View Posts
AJ Freely AJ Freely 9 months ago
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 9 months ago
INZY new 52 week high
👍️0
INFINITI INFINITI 1 year ago
Loading
👍️0
Jess070283 Jess070283 1 year ago
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 1 year ago
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 1 year ago
Quietest board out there
👍️0
ErnieBilco ErnieBilco 2 years ago
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 2 years ago
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 2 years ago
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 2 years ago
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 2 years ago
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 2 years ago
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 2 years ago
PT > 33.00
👍️0
crudeoil24 crudeoil24 2 years ago
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

Your Recent History

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved